The historical rank and industry rank for Recursion Pharmaceuticals's Net Margin % or its related term are showing as below:
RXRX'
s Net Margin % Range Over the Past 10 Years
Min: -3616.54 Med: -868.29 Max: -603.5
Current: -851.53
RXRX's Net Margin % is ranked worse than 77.47% of 941
companies
in the Biotechnology industry
Industry Median: -88.3
vs RXRX: -851.53
Recursion Pharmaceuticals (NAS:RXRX) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Recursion Pharmaceuticals Net Margin % Related Terms
Recursion Pharmaceuticals Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Recursion Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recursion Pharmaceuticals Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Recursion Pharmaceuticals's Net Margin % distribution charts can be found below:
* The bar in red indicates where Recursion Pharmaceuticals's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Recursion Pharmaceuticals (RXRX) has a Net Margin % of -1,864.85% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Recursion Pharmaceuticals and its competitors. According to the industry distribution chart, Recursion Pharmaceuticals ranks #729 out of 941 companies in the Biotechnology industry, placing it in the top 77.5%.
Is Recursion Pharmaceuticals' Net Margin % too high?
Recursion Pharmaceuticals' current Net Margin % is -1,864.85%. Based on the distribution chart, Recursion Pharmaceuticals ranks #729 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Recursion Pharmaceuticals has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Recursion Pharmaceuticals' Net Margin % compare to ABSI and GLUE?
According to the Biotechnology industry distribution chart, Recursion Pharmaceuticals ranks #729 out of 941 companies for Net Margin %. This places Recursion Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Recursion Pharmaceuticals and its competitors. Recursion Pharmaceuticals's current Net Margin % is -1,864.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recursion Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Recursion Pharmaceuticals (RXRX) is currently considered Fairly Valued. The stock's GF Value™ is $4.14, compared to a current price of $3.82 — trading 7.9% below its estimated fair value. The current Net Margin % is -1,864.85%. Recursion Pharmaceuticals' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Recursion Pharmaceuticals (RXRX), the current Net Margin % is -1,864.85% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Recursion Pharmaceuticals (RXRX) Overvalued in 2026?
Based on GuruFocus' analysis, Recursion Pharmaceuticals stock appears to be undervalued.
The current stock price of $3.82 is trading 7.9% below its estimated GF Value™ of $4.14.
GuruFocus considers Recursion Pharmaceuticals to be Fairly Valued.
Key valuation signals for RXRX:
Net Margin %: -1,864.85%
GF Value™: $4.14 vs. price of $3.82 (7.9% below fair value)
No single metric tells the full story. See the RXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
77GF Score
Get the complete analysis for RXRX
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RXRX has been successfully added to your 
